Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 18, 2021

Cala Health and UCSF to develop neuromodulation therapies

The technologies licenced from UCSF will boost Cala Health’s pipeline of neurology treatments.

Cala Health has collaborated with the University of California, San Francisco (UCSF), US, to develop tailored peripheral nerve stimulation treatments based on the former’s neuromodulation and data science platform technology.

A bioelectronic medicine company, Cala Health combines innovations in neuroscience and technology to create wearable therapies for chronic diseases.

As part of the alliance, the company will collaborate with UCSF Weill Institute of Neuroscience neurology associate professor and neural engineering expert Dr Karunesh Ganguly, as well as others, to develop non-invasive therapies for critical neurological diseases.

Cala Health founder and chief scientific officer Kate Rosenbluth said: “Dr Ganguly’s pioneering research on the precise targeting of electrical stimulation to modulate neural networks provides an exciting path to personalise therapy to each patient.

“This partnership takes Cala Health one step closer to reaching our goal to give the millions of patients suffering from debilitating neurological disorders access to non-invasive, efficacious therapies that improve their quality of life.”

The technologies licenced from UCSF under this collaboration will aid Cala Health to grow its pipeline of neurology treatments.

Content from our partners
“Everything is custom”: Behind the scenes of medical wire solutions
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials

Furthermore, the collaboration will boost the company’s mechanistic research to create new tailored treatments as well as aiding in incorporating its data science platform to develop software-enabled customised treatment insights for patients in a timely manner.

Ganguly said: “In my clinical work, I see the profound impacts of motor impairments from a wide range of neurological conditions such as brain injury and Parkinson’s disease, and we are committed to advancing new treatments to enhance motor function.

“The UCSF team looks forward to a fruitful partnership with Cala to advance peripheral nerve stimulation as a treatment to improve motor function.”

Recently, Cala Health introduced its transcutaneous afferent patterned stimulation therapy, Cala Trio, for treating hand tremors in the movement disorder essential tremor.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU